The increasing complexity of emerging therapies and the need for faster development have led to the adoption of advanced ...

With accelerated computing powering every step of the process from data preparation to training, fine-tuning and model evaluation, Amgen is moving towards significantly improving drug development ...

Analyst Colleen M. Kusy of Robert W. Baird reiterated a Buy rating on Spyre Therapeutics (SYRE – Research Report), retaining the price ...

Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.

Shares in Sangamo Therapeutics (Nasdaq: SGMO) surged around 40% on Tuesday, following the announcement that the US Food and ...

Sangamo Therapeutics shares rose after the company said the outcome of a recent successful interaction with the Food and Drug Administration provided a clear regulatory pathway to accelerated approval ...

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...

In this article, Michael Landau outlines factors driving biopharma companies to rely on CDMOs and highlights some of the contributions that CDMOs bring to their customers. Never miss a story ...

With the global market for early-phase development services valued at approximately $15 billion, Accelevate™ is uniquely positioned to meet the growing demand for accelerated drug development ...

Accenture plans to customize a NIM Agent Blueprint to the specific needs of drug development programs by partnering with biopharmas to optimize the molecule generation step within the MolMIM NIM.

New Platform Reduces IND Submission Timelines for Small and Mid-Sized Pharma Companies. HUNT VALLEY, Md., October 08, 2024--(BUSINESS WIRE)--Pharmaceutics International, Inc. (Pii), a trusted ...